Burgos Leire, Paiva Bruno
Universidad De Navarra, Pamplona, Spain.
Methods Mol Biol. 2018;1792:15-34. doi: 10.1007/978-1-4939-7865-6_2.
Here, we describe the detailed protocol for minimal residual disease (MRD) assessment as well as circulating tumor cell (CTC) detection in patients with plasma cell disorders using the next-generation flow (NGF) method developed by EuroFlow. This includes the previous setup of flow cytometers, preparation and staining of samples, cell acquisition, quality control of instruments, methods and samples, as well as data interpretation to monitor MRD and CTCs with great sensitivity. It should be noted that the NGF method fully described below can be equally applied to monitor MRD in patients with systemic light-chain amyloidosis and to detect occult bone marrow involvement in patients with solitary plasmocytoma.
在此，我们描述了使用欧洲流式细胞术（EuroFlow）开发的新一代流式细胞术（NGF）方法，对浆细胞疾病患者进行微小残留病（MRD）评估以及循环肿瘤细胞（CTC）检测的详细方案。这包括流式细胞仪的前期设置、样本的制备和染色、细胞采集、仪器、方法和样本的质量控制，以及用于高灵敏度监测MRD和CTC的数据解读。需要注意的是，以下详细描述的NGF方法同样可用于监测系统性轻链淀粉样变性患者的MRD，以及检测孤立性浆细胞瘤患者隐匿的骨髓受累情况。
